Potential to return to greatness with the approval of a breakthrough cancer therapy later this year. - Associate Director bei Merck: Mitarbeiterbewertung

3,0
25. März 2014
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Some very bright people still remain, although many excellent people have left. Vacation policy is generous.

Kontras

Constant layoffs, and too much focus on financial results, and not enough on the patient. Employee morale is low. Senior management, with the exception of the Research division president, is poor. Raises are sub-inflation on average. Bonuses lower this year than in any year in recent memory.

Mehr Bewertungen zu Merck entdecken

5,0
30. Juni 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Excellent company to work with.

Kontras

No cons encountered so far

4,0
30. Juni 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Great benefits like medical/dentist/vision, pension, stock option, 401k match. Co workers are excellent, pretty good on site symposiums, lot of diversity clubs/activities. Innovation is extremely welcomed. Diversity in research portfolio. AI/ML is heavily invested to make databases more efficient.

Kontras

Micro managing, especially within the biologics department, potentially others. Promotions are limited, and pay bump is poor. Company invests too much in buying companies rather than keeping talent - lay offs let go of great talented people. Merck is afraid of investing into exploratory biology and doesn’t take risk - they even admit they would rather see other companies clinical data or R&D data rather than taking a risk. Although it’s slow going in building new software, current databases are slow and needs much improvement. Extremely poor work/life balance.

Bewertungen anzeigen nach: Hilfreich|Sterne|Datum|Alle